pharma research

View All

pharma-news
Eli Lilly’s COVID-19 Antibody trial; Approval for Oriahnn; Gilead’s Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19

Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555.  LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people g...

Find More

pharma news
Acquisition of ArQule; Synthorx; and Zentalis nabs a raise

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for a total amount of USD 2.7 Billion. ArQule is a biopharmaceutical, which is focused on kinase inhibitor discovery, finding cures for cancer p...

Find More

Recent Pharma News
FDA’s approval to Pfizer’s Zirabev; Launch of Century Therapeutics; Imbruvica’s recommendation from CHMP

Pfizer’s Zirabev gets FDA nod for the treatment of five types of cancer The US FDA has approved Zirabev (bevacizumab-bvzr), a drug developed by Pfizer, for the treatment of five different types of cancer namely metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous no...

Find More

transthyretin amyloidosis
Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation

Axovant rely on new gene therapy, Rise in Shares  Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark Therapeutics’ Former CTO Fraser Wright, Ph.D has been hired as its new CTO. Axovant expects to stimulate a phase 1/2 dose escalation stu...

Find More

transthyretin amyloidosis
Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CD...

Find More

Signal Transducer and Activator of Transcription
STAT INHIBITORS- Highly active Pipeline

Signal Transducer and Activator of Transcription (STAT ) is a family of cytoplasmic transcription factors comprising of 7 members-STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. The STAT factors are activated by tyrosine kinase which could be either receptor associated as Janus Kinase (JAKs) or intrinsic tyro...

Find More

CELIAC DISEASE
Celiac Disease – Intestinal damage of Gluten

Celiac Disease (Gluten-Sensitive Enteropathy) is a chronic, autoimmune, inflammatory disease of the small intestine characterized by damage to the lining of the small intestine and typically leads to dyspepsia, malabsorption and a variety of other symptoms. Individuals with Celiac Disease carry DQ2 or DQ8 MHC class ...

Find More

Delveinsight
Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH)

NASH is defined as the most common form of Nonalcoholic fatty liver disease (NAFLD). The disease is characterized by a spectrum of symptoms including simple steatosis, increased levels of fibrosis, and cirrhosis of the liver. NASH can also result in advanced fibrosis, NASH cirrhosis, and NASH Decompensated Cirrhosi...

Find More

BioGen
The Business Cocktail : Latest Pharma deals

Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the develo...

Find More

severe combined Immunodeficiency
Immune Checkpoint Activators (ICA): Dynamic Therapeutic Targets

Immune checkpoints are the regulators of immune activation. They play a key role in maintaining immune homeostasis and preventing autoimmunity. Immune checkpoint activators are small molecules responsible for maintenance, modulation, and regulation of immune responses. Its significance in immune-therapeutics is back...

Find More